BeyoND is an open-label study of ND0612 designed to evaluate the long-term safety and tolerability of ND0612 in patients with Parkinson’s disease experiencing motor fluctuations.

With over 100 patients having completed the first 12 months in the BeyoND study, to date the study has shown ND0612 to be safe with generally mild to moderate infusion site reactions typical of a subcutaneous mode of continuous drug delivery, and with no unexpected TEAEs for systemic levodopa treatment.

Long-term data will continue to be collected from patients enrolled in the study extension, some of whom are now in their 5th year of ND0612 treatment. More information can be found at clinicaltrials.gov.